Search results
Results from the WOW.Com Content Network
In combination with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer (BTC). [13] In June 2024, the US FDA approved durvalumab with carboplatin plus paclitaxel, followed by single-agent durvalumab, for adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient. [15 ...
Gemcitabine, sold under the brand name Gemzar, among others, [1] is a chemotherapy medication used to treat cancers. [2] It is used to treat testicular cancer , [ 3 ] breast cancer , ovarian cancer , non-small cell lung cancer , pancreatic cancer , and bladder cancer .
Cisplatin is a chemical compound with formula cis-[Pt(NH 3) 2 Cl 2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers . [ 3 ] These include testicular cancer , ovarian cancer , cervical cancer , bladder cancer , head and neck cancer , esophageal cancer , lung cancer ...
Candida albicans infection; Candida parapsilosis infection; Cytomegalovirus infection; diphtheria; human coronavirus infection; respiratory distress syndrome; measles; meconium aspiration syndrome
Patients and their diseases are profiled in order to identify the most effective treatment for their specific case. Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, [1] others being hormonal therapy and cytotoxic chemotherapy.
Mechanism of action of gemtuzumab ozogamicin. Gemtuzumab ozogamicin is a recombinant, humanized anti-CD33 monoclonal antibody (IgG4 κ antibody hP67.6) covalently attached to the cytotoxic antitumor antibiotic calicheamicin (N-acetyl-γ-calicheamicin) payload via a bifunctional linker (4-(4-acetylphenoxy)butanoic acid).
Ototoxicity (damage to the inner ear) is a common side effect of platinum based drugs that can produce symptoms such as dizziness and vertigo. [131] [132] Children treated with platinum analogues have been found to be at risk for developing hearing loss. [133] [134] [135]
The chemotherapeutic agent of choice depends on the NSCLC subtype: cisplatin plus gemcitabine for squamous cell carcinoma, cisplatin plus pemetrexed for non-squamous cell carcinoma. [47] Immune checkpoint inhibitors are most effective against tumors that express the protein PD-L1, but are sometimes effective in those that do not. [48]